J
J Kienast
Researcher at University of Münster
Publications - 29
Citations - 1114
J Kienast is an academic researcher from University of Münster. The author has contributed to research in topics: Septic shock & Sepsis. The author has an hindex of 14, co-authored 29 publications receiving 1069 citations.
Papers
More filters
Journal ArticleDOI
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.
Rolf M. Mesters,Pier Mannuccio Mannucci,Raffaella Coppola,Thomas Keller,H. Ostermann,J Kienast +5 more
TL;DR: Septic shock in neutropenic patients is associated with increased thrombin generation, and both FVIIa and AT III measurements are sensitive markers of an unfavorable prognosis.
Journal ArticleDOI
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Teresa Padró,Ralf Bieker,Sandra Ruiz,Martin Steins,S. Retzlaff,Horst Bürger,T. Büchner,Torsten Kessler,Federico Santiago Herrera,J Kienast,Carsten Müller-Tidow,Hubert Serve,Wolfgang E. Berdel,Rolf M. Mesters +13 more
TL;DR: Results provide evidence for increased expression of VEGF/VEGFR-2 of leukemic blasts and correlation with angiogenesis in the bone marrow of AML patients and might constitute promising targets for antiangiogenic and antileukemic treatment strategies in AML.
Journal ArticleDOI
Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
TL;DR: Septic shock in leukocytopenia is associated with significant activation of the fibrinolytic system presumably as a response of the vascular endothelium to inflammatory injury and PAI activity measurements are sensitive markers of an unfavourable prognosis.
Journal ArticleDOI
Quantification of Plasminogen Activators and Their Inhibitors in the Aortic Vessel Wall in Relation to the Presence and Severity of Atherosclerotic Disease
TL;DR: A large excess of PAI-1 over PA concentrations, particularly in the intimal layer, characterizes atherosclerotic lesions of the human aorta and suggests that PA action is locally confined and counterbalanced by enhanced PAI expression and accumulation.
Journal ArticleDOI
Biologic effects of recombinant hirudin (CGP 39393) in human volunteers
Marc Verstraete,Michael T. Nurmohamed,J Kienast,Mathias Siebeck,Gerda Silling-Engelhardt,Harry R. Büller,B Hoet,J. Bichler,Philippe Close,Philippe Close +9 more
TL;DR: The activated partial thromboplastin time test seems to be well suited to monitor the anticoagulant effect of recombinant hirudin because the dose effect is linear up to 0.5 mg/kg of subcutaneous CGP 39393.